HB Sweets Member Companies
Harlem Biospace is a hub for biotech innovators in NYC and the core of this community are the companies that call Hb home. Through a competitive application cycle every six months, we select some of the region’s most promising early stage ventures to work from Hb.
Our current batch of companies includes:
Developing new drugs for osteoarthritis.
Our drugs may become a first disease-modifying therapy for osteoarthritis. Currently, our lead candidate is being studied in animals, and it has the potential to enter clinical trials in 2021.
Contact: ang.li@avidenceinc.com
BaconBio aims to design and cultivate scalable lab grown meat cell lines for a consumer-focused food product. By taking an R&D focused angle in the burgeoning space, we believe this technology can ultimately scale into other applications including regenerative medicine.
Contact: info@baconbio.com
Bioworkshop is a New York based biotech start-up which is developing microfluidic biochips that model human skeletal tissues and diseases. Our technology will make drug research and development more accurate, quicker and cheaper. Beyond that our platform will eventually facilitate the development of personalised medicines, target other organs and be applied to a range of industries beyond healthcare.
Contact: info@thebioworkshop.com
Genetics research in canines.
CytoDel has a developed a platform producing recombinant derivatives of botulinum toxin (rBoTs) with applications in biodefense and chronic pain syndromes. Two very differentapplications have been developed, both based on the unique ability of rBoTs to specifically target and deliver the protease portion of their polypeptide chain to the presynaptic compartment of neurons. In the first application, Cyto-014 is a potency-modulated rBoT in which the catalytic activity of the rBoT protease is modulated by amino acid substitution to improve safety and modify targeting. The lead product for this application group is Cyto-014, an rBoT with a single amino acid substitution that has been shown to significantly reduce hyperalgesia in murine models of knee OA, and which colocalizes with NaV1.8 nociceptors after intra-articular injection. In the second group of applications, the rBoT protease is completely inactivated while maintaining its neuronal targeting, and used as a molecular vehicle to deliver VHH antibodies to the neuronal cytoplasm. The lead product for this application group is Cyto-111. Developed for biodefense, Cyto-111 delivers a therapeutic antibody to the presynaptic compartment of intoxicated neurons, and has been demonstrated to rescue intoxicated animals at times post-exposure when conventional antibodies are ineffective.
Haystack Medical is revolutionizing inner ear medicine.
Over 30 million US patients are in need of better options for inner ear maladies. Haystack's technology offers a major breakthrough through its microneedles, providing safe and effective delivery of therapeutics directly into the inner ear. Developed at Columbia University, the technology has been rigorously tested and proven effective in both guinea pig and human cadaveric studies, with 20+ peer-reviewed publications and multiple granted and pending patents.
Contact: aykut@haystackmedical.com
Providing underserved students with hands-on science and engineering educational and mentorship experiences.
Contact: hello@hypothekids.org
MicroRNA for personalized medicine - improved diagnostics & disease management of pulmonary hypertension.
Contact: Gabriele Grunig
Shodex™ manufactures innovative polymer-based HPLC columns including size-exclusion chromatography, HILIC, and sugar analysis columns.
Contact: Ronald Benson
UmAb Biosystems focuses on antibody libraries, discovery, engineering, and analysis, helping biotech and research partners identify, design, and optimize fully human antibodies for therapeutic development. Using advanced phage display and antibody engineering technologies, UmAb supports the full antibody development process from early discovery through analysis to reduce risk and accelerate results.
Revolutionary nanomedicine bone targeted drug delivery and controlled release platform technology for the treatment of musculoskeletal conditions.
Contact: wntscientific@yahoo.com
Highlighted Alumni
Developing a novel series of small molecule therapeutics for suppressing tumors.
Grow your own bone.
Developing mitochondrial DNA based biomarkers for cancer and developmental disorders.
Reinventing allergy diagnostics.
Formulating novel antimicrobial polymers.
The future of sweet.
Developing therapeutics to treat diseases caused by imbalances in the gut microbial ecosystem.
Tissue models for rapid testing of the safety and efficacy of drugs with an initial focus on cardiological microtissues.